PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company [NASDAQ: MDCO] today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s new drug application (NDA) for Cleviprex™ (clevidipine butyrate injectable emulsion) for the treatment of acute hypertension. If approved, Cleviprex will be the first new treatment for acute hypertension in more than 10 years.
